Overview

Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
0
Participant gender:
All
Summary
The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Axitinib
Endothelial Growth Factors
Mitogens
Criteria
Inclusion Criteria:

- Histologically documented RCC with metastases.

- Failure of 1 prior cytokine-based therapy (interleukin-2 and/or interferon) due to
disease progression or unacceptable treatment-related toxicity

Exclusion Criteria:

- Any prior systemic treatment for Renal Cell Carcinoma [RCC] other than 1 prior
cytokine-based treatment regimen. Cytokine-based regimens containing thalidomide or an
anti-angiogenesis agent are not allowed.

- Inability to take oral medication